Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue

  • Villarroya, Joan
  • Villarroya, Francesc
  • Gallego-Escuredo, José M.
  • Delgado‐Anglés, Alejando
  • Cairó, Montserrat
  • Moure, Ricardo
  • Mateo, Gracia M.
  • Domingo, Joan C.
  • Domingo, Pere
  • Giralt, Marta
Fibroblast growth factor 21 (FGF21) has been proposed to be an antiaging hormone on the basis of experimental studies in rodent models. However, circulating FGF21 levels are increased with aging in rodents and humans. Moreover, despite the metabolic health‐promoting effects of FGF21, the levels of this hormone are increased under conditions such as obesity and diabetes, an apparent incongruity that has been attributed to altered tissue responsiveness to FGF21. Here, we investigated serum FGF21 levels and expression of genes encoding components of the FGF21response molecular machinery in adipose tissue from healthy elderly individuals (≥70 years old) and young controls. Serum FGF21 levels were increased in elderly individuals and were positively correlated with insulinemia and HOMA‐IR, indices of mildly deteriorated glucose homeostasis. Levels of β‐Klotho, the coreceptor required for cellular responsiveness to FGF21, were increased in subcutaneous adipose tissue from elderly individuals relative to those from young controls, whereas FGF receptor‐1 levels were unaltered. Moreover, total ERK1/2 protein levels were decreased in elderly individuals in association with an increase in the ERK1/2 phosphorylation ratio relative to young controls. Adipose explants from aged and young mice respond similarly to FGF21 “ex vivo”. Thus, in contrast to what is observed in obesity and diabetes, high levels of FGF21 in healthy aging are not associated with repressed FGF21‐responsiveness machinery in adipose tissue. The lack of evidence for impaired FGF21 responsiveness in adipose tissue establishes a distinction between alterations in the FGF21 endocrine system in aging and chronic metabolic pathologies., This work was funded in part by Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (PI14/00700, PI14/00063, PI17/00420), Ministerio de Economía y Competitividad (SAF2017‐85722), cofinanced by the European Regional Development Fund (ERDF).
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Reciprocal effects of antiretroviral drugs used to treat HIV infection on the fibroblast growth factor 21/β-Klotho System

  • Moure, Ricardo
  • Domingo, Pere
  • Villarroya, Joan
  • Gasa, Laura
  • Gallego-Escuredo, José M.
  • Quesada-López, Tania
  • Morón-Ros, Samantha
  • Maroto, Alberto F.
  • Mateo, Gracia M.
  • Domingo, Joan C.
  • Villarroya, Francesc
  • Giralt, Marta
Following antiretroviral therapy, HIV-infected patients show increased circulating levels of the antidiabetic hormone fibroblast growth factor 21 (FGF21). In contrast, the expression of the FGF21-obligatory coreceptor -Klotho (KLB) is reduced in target tissues. This situation is comparable to the FGF21 resistance status observed in obesity and type 2 diabetes. Here, we performed the first systematic study of the effects of distinct members of different antiretroviral drug classes on the FGF21/KLB system in human hepatic, adipose, and skeletal muscle cells. Most protease inhibitors and the nonnucleoside reverse transcriptase inhibitor efavirenz induced FGF21 gene expression. Neither nucleoside reverse transcriptase inhibitors nor the viral entry inhibitor maraviroc had any effect. Among the integrase inhibitors, elvitegravir significantly induced FGF21 expression, whereas raltegravir had minor effects only in adipose cells. In human hepatocytes and adipocytes, known target cells of FGF21 action, efavirenz, elvitegravir, and the lopinavir-ritonavir combination exerted inhibitory effects on KLB gene expression. Drug treatments that elicited FGF21 induction/KLB repression were those found to induce endoplasmic reticulum (ER) stress and oxidative stress. Notably, the pharmacological agents thapsigargin and tunicamycin, which induce these stress pathways, mimicked the effects of drug treatments. Moreover, pharmacological inhibitors of either ER or oxidative stress significantly impaired lopinavir–ritonavir-induced regulation of FGF21, but not KLB. In conclusion, the present in vitro screen study identifies the antiretroviral drugs that affect FGF21/KLB expression in human cells. The present results could have important implications for the management of comorbidities resulting from side effects of specific antiretroviral drugs for the treatment of HIV-infected patients., This research was supported by grants from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III ([ISCIII] PI14/00063, PI14/00700, PI17/00420, and PI17/ 00498) and the Ministerio de Economía y Competitividad ([MINECO] SAF2014-23636 and SAF2017-85722), cofinanced by the European Regional Development Fund (ERDF) and Red de Investigación en SIDA (RD16/0025/0006), ISCIII, Spain. R.M. was supported by a PFIS PhD scholarship from AES, ISCIII, MINECO, Spain. T.Q.-L. was supported by a CONACyT (National Council for Science and Technology in Mexico) PhD scholarship. J.V. and J.M.G.-E. are “Juan de la Cierva” (MINECO, Spain) and “Sara Borrell” (ISCIII, Spain) postdoctoral researchers, respectively.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy

  • Domínguez‐González, Cristina
  • Badosa, María Carmen
  • Madruga, Marcos
  • Martí, Itxaso
  • Paradas, Carmen
  • Ortez, Carlos
  • Díaz-Manera, Jordi
  • Berardo, Andrés
  • Alonso-Pérez, Jorge
  • Trifunov, Selena
  • Cuadras, Daniel
  • Kalko, Susana Graciela
  • Blázquez-Bermejo, Cora
  • Cámara, Yolanda
  • Martí, Ramón
  • Mavillard, Fabiola
  • Martín, Miguel Ángel
  • Montoya, Julio
  • Ruiz-Pesini, Eduardo
  • Villarroya, Joan
  • Montero, Raquel
  • Villarroya, Francesc
  • Artuch, Rafael
  • Hirano, Michio
  • Nascimento, Andrés
  • Jiménez-Mallebrera, Cecilia
GDF-15 is a biomarker for mitochondrial diseases. We investigated the application of GDF-15 as biomarker of disease severity and response to deoxynucleoside treatment in patients with thymidine kinase 2 (TK2) deficiency and compared it to FGF-21. GDF-15 and FGF-21 were measured in serum from 24 patients with TK2 deficiency treated 1–49 months with oral deoxynucleosides. Patients were grouped according to age at treatment and biomarkers were analyzed at baseline and various time points after treatment initiation. GDF-15 was elevated on average 30-fold in children and 6-fold in adults before the start of treatment. There was a significant correlation between basal GDF-15 and severity based on pretreatment distance walked (6MWT) and weight (BMI). During treatment, GDF-15 significantly declined, and the decrease was accompanied by relevant clinical improvements. The decline was greater in the paediatric group, which included the most severe patients and showed the greatest clinical benefit, than in the adult patients. The decline of FGF-21 was less prominent and consistent. GDF-15 is a potential biomarker of severity and of therapeutic response for patients with TK2 deficiency. In addition, we show evidence of clinical benefit of deoxynucleoside treatment, especially when treatment is initiated at an early age., This work was supported by research grants of Plan Nacional de I + D + I and Instituto de Salud Carlos III (ISCIII), Subdirección General de Evaluación y Fomento de la Investigación Sanitaria, projects PI16/01843 (CP), PI16/00579 and CP09/00011 (CJM), PI15/00431 (MAM), PI17/00109 (RA) and PI18/01574 (RM), co-funded with European Regional Development Fund (ERDF) “A way to achieve Europe”; multicentric grant funded by the ISCIII (PMP15/00025, MAM, RM, CP), Grants of the Ministerio de Ciencia, Innovación y Universidades SAF2017-85722 (FV) and SAF2017-87506-R (YC), the Muscular Dystrophy Association grant 577391 (MH), and the Arturo Estopinan TK2 Research Fund (MH).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

ARMCX3 Mediates Susceptibility to Hepatic Tumorigenesis Promoted by Dietary Lipotoxicity

  • Mirra, Serena
  • Gavaldà-Navarro, Aleix
  • Manso, Yasmina
  • Serrat, Román
  • Salcedo Allende, Maria Teresa
  • Minguez Rosique, Beatriz
  • Higuera Urbano, Monica
  • Balibrea, José M.
Lipotoxicitat; Obesitat, Lipotoxicity; Obesity, Lipotoxicidad; Obesidad, ARMCX3 is encoded by a member of the Armcx gene family and is known to be involved in nervous system development and function. We found that ARMCX3 is markedly upregulated in mouse liver in response to high lipid availability, and that hepatic ARMCX3 is upregulated in patients with NAFLD and hepatocellular carcinoma (HCC). Mice were subjected to ARMCX3 invalidation (inducible ARMCX3 knockout) and then exposed to a high-fat diet and diethylnitrosamine-induced hepatocarcinogenesis. The effects of experimental ARMCX3 knockdown or overexpression in HCC cell lines were also analyzed. ARMCX3 invalidation protected mice against high-fat-diet-induced NAFLD and chemically induced hepatocarcinogenesis. ARMCX3 invalidation promoted apoptotic cell death and macrophage infiltration in livers of diethylnitrosamine-treated mice maintained on a high-fat diet. ARMCX3 downregulation reduced the viability, clonality and migration of HCC cell lines, whereas ARMCX3 overexpression caused the reciprocal effects. SOX9 was found to mediate the effects of ARMCX3 in hepatic cells, with the SOX9 interaction required for the effects of ARMCX3 on hepatic cell proliferation. In conclusion, ARMCX3 is identified as a novel molecular actor in liver physiopathology and carcinogenesis. ARMCX3 downregulation appears to protect against hepatocarcinogenesis, especially under conditions of high dietary lipid-mediated hepatic insult., The study was supported by grant 201337-30-31-32 Fundació la Marató de TV3, grant SAF2017-85722R (Ministerio de Economia y Competitividad) to F.V., grant PID2019-106764RB-C21/ AEI/ 10.13039/501100011033 from the Spanish Ministry of Science and a collaborative grant from CIBERNED to E.S, grant PI18/00961 (Instituto de Salud Carlos III) to B.M, and the Hepacare Project grant from Fundación La Caixa to M.A.A. and C.B. F.V. and E.S. are ICREA researchers.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Reciprocal effects of antiretroviral drugs used to treat HIV infection on the fibroblast growth factor 21/β-Klotho System

  • Moure, Ricardo
  • Domingo, Pere
  • Villarroya, Joan
  • Gasa, Laura
  • Gallego-Escuredo, José M.
  • Quesada-López, Tania
  • Morón-Ros, Samantha
  • Maroto, Alberto F.
  • Mateo, Gracia M.
  • Domingo, Joan C.
  • Villarroya, Francesc
  • Giralt, Marta
Following antiretroviral therapy, HIV-infected patients show increased circulating levels of the antidiabetic hormone fibroblast growth factor 21 (FGF21). In contrast, the expression of the FGF21-obligatory coreceptor -Klotho (KLB) is reduced in target tissues. This situation is comparable to the FGF21 resistance status observed in obesity and type 2 diabetes. Here, we performed the first systematic study of the effects of distinct members of different antiretroviral drug classes on the FGF21/KLB system in human hepatic, adipose, and skeletal muscle cells. Most protease inhibitors and the nonnucleoside reverse transcriptase inhibitor efavirenz induced FGF21 gene expression. Neither nucleoside reverse transcriptase inhibitors nor the viral entry inhibitor maraviroc had any effect. Among the integrase inhibitors, elvitegravir significantly induced FGF21 expression, whereas raltegravir had minor effects only in adipose cells. In human hepatocytes and adipocytes, known target cells of FGF21 action, efavirenz, elvitegravir, and the lopinavir-ritonavir combination exerted inhibitory effects on KLB gene expression. Drug treatments that elicited FGF21 induction/KLB repression were those found to induce endoplasmic reticulum (ER) stress and oxidative stress. Notably, the pharmacological agents thapsigargin and tunicamycin, which induce these stress pathways, mimicked the effects of drug treatments. Moreover, pharmacological inhibitors of either ER or oxidative stress significantly impaired lopinavir–ritonavir-induced regulation of FGF21, but not KLB. In conclusion, the present in vitro screen study identifies the antiretroviral drugs that affect FGF21/KLB expression in human cells. The present results could have important implications for the management of comorbidities resulting from side effects of specific antiretroviral drugs for the treatment of HIV-infected patients., This research was supported by grants from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III ([ISCIII] PI14/00063, PI14/00700, PI17/00420, and PI17/ 00498) and the Ministerio de Economía y Competitividad ([MINECO] SAF2014-23636 and SAF2017-85722), cofinanced by the European Regional Development Fund (ERDF) and Red de Investigación en SIDA (RD16/0025/0006), ISCIII, Spain. R.M. was supported by a PFIS PhD scholarship from AES, ISCIII, MINECO, Spain. T.Q.-L. was supported by a CONACyT (National Council for Science and Technology in Mexico) PhD scholarship. J.V. and J.M.G.-E. are “Juan de la Cierva” (MINECO, Spain) and “Sara Borrell” (ISCIII, Spain) postdoctoral researchers, respectively.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue

  • Villarroya, Joan
  • Villarroya, Francesc
  • Gallego-Escuredo, José M.
  • Delgado‐Anglés, Alejando
  • Cairó, Montserrat
  • Moure, Ricardo
  • Mateo, Gracia M.
  • Domingo, Joan C.
  • Domingo, Pere
  • Giralt, Marta
Fibroblast growth factor 21 (FGF21) has been proposed to be an antiaging hormone on the basis of experimental studies in rodent models. However, circulating FGF21 levels are increased with aging in rodents and humans. Moreover, despite the metabolic health‐promoting effects of FGF21, the levels of this hormone are increased under conditions such as obesity and diabetes, an apparent incongruity that has been attributed to altered tissue responsiveness to FGF21. Here, we investigated serum FGF21 levels and expression of genes encoding components of the FGF21response molecular machinery in adipose tissue from healthy elderly individuals (≥70 years old) and young controls. Serum FGF21 levels were increased in elderly individuals and were positively correlated with insulinemia and HOMA‐IR, indices of mildly deteriorated glucose homeostasis. Levels of β‐Klotho, the coreceptor required for cellular responsiveness to FGF21, were increased in subcutaneous adipose tissue from elderly individuals relative to those from young controls, whereas FGF receptor‐1 levels were unaltered. Moreover, total ERK1/2 protein levels were decreased in elderly individuals in association with an increase in the ERK1/2 phosphorylation ratio relative to young controls. Adipose explants from aged and young mice respond similarly to FGF21 “ex vivo”. Thus, in contrast to what is observed in obesity and diabetes, high levels of FGF21 in healthy aging are not associated with repressed FGF21‐responsiveness machinery in adipose tissue. The lack of evidence for impaired FGF21 responsiveness in adipose tissue establishes a distinction between alterations in the FGF21 endocrine system in aging and chronic metabolic pathologies., This work was funded in part by Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (PI14/00700, PI14/00063, PI17/00420), Ministerio de Economía y Competitividad (SAF2017‐85722), cofinanced by the European Regional Development Fund (ERDF).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System

  • Moure, Ricardo
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Villarroya, Joan
  • Gasa, Laura
  • Gallego-Escuredo, José Miguel
  • Quesada-López, Tania|||0000-0002-7818-4351
  • Morón-Ros, Samantha|||0000-0002-6205-2442
  • Maroto, Alberto F.
  • Mateo, Gracia M.
  • Domingo, Joan Carles|||0000-0002-6356-0836
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Girlat, Marta|||0000-0001-7968-4190
Following antiretroviral therapy, HIV-infected patients show increased circulating levels of the antidiabetic hormone fibroblast growth factor 21 (FGF21). In contrast, the expression of the FGF21-obligatory coreceptor β-Klotho (KLB) is reduced in target tissues. This situation is comparable to the FGF21 resistance status observed in obesity and type 2 diabetes. Here, we performed the first systematic study of the effects of distinct members of different antiretroviral drug classes on the FGF21/KLB system in human hepatic, adipose, and skeletal muscle cells. Most protease inhibitors and the nonnucleoside reverse transcriptase inhibitor efavirenz induced FGF21 gene expression. Neither nucleoside reverse transcriptase inhibitors nor the viral entry inhibitor maraviroc had any effect. Among the integrase inhibitors, elvitegravir significantly induced FGF21 expression, whereas raltegravir had minor effects only in adipose cells. In human hepatocytes and adipocytes, known target cells of FGF21 action, efavirenz, elvitegravir, and the lopinavir-ritonavir combination exerted inhibitory effects on KLB gene expression. Drug treatments that elicited FGF21 induction/KLB repression were those found to induce endoplasmic reticulum (ER) stress and oxidative stress. Notably, the pharmacological agents thapsigargin and tunicamycin, which induce these stress pathways, mimicked the effects of drug treatments. Moreover, pharmacological inhibitors of either ER or oxidative stress significantly impaired lopinavir-ritonavir-induced regulation of FGF21, but not KLB. In conclusion, the present in vitro screen study identifies the antiretroviral drugs that affect FGF21/KLB expression in human cells. The present results could have important implications for the management of comorbidities resulting from side effects of specific antiretroviral drugs for the treatment of HIV-infected patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy

  • Domínguez-González, Cristina|||0000-0001-5151-988X
  • Badosa, Carmen
  • Madruga-Garrido, Marcos
  • Martí, Itxaso|||0000-0003-0578-9568
  • Paradas, Carmen|||0000-0002-6917-2236
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Berardo, Andres
  • Alonso Pérez, Jorge|||0000-0001-8866-5186
  • Trifunov, Selena|||0000-0002-1807-9621
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Kalko, Susana G.|||0000-0002-6701-0233
  • Blázquez-Bermejo, Cora
  • Cámara, Yolanda|||0000-0003-2458-6942
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Mavillard, Fabiola|||0000-0002-1460-0483
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Montoya, Julio|||0000-0003-1770-6299
  • Ruiz-Pesini, Eduardo|||0000-0002-0269-7337
  • Villarroya, Joan
  • Montero, Raquel|||0000-0003-0609-5701
  • Villarroya, Francesc|||0000-0003-1266-9142
  • Artuch, R.|||0000-0002-3422-9685
  • Hirano, Michio|||0000-0002-7070-7402
  • Nascimento, Andrés
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
GDF-15 is a biomarker for mitochondrial diseases. We investigated the application of GDF-15 as biomarker of disease severity and response to deoxynucleoside treatment in patients with thymidine kinase 2 (TK2) deficiency and compared it to FGF-21. GDF-15 and FGF-21 were measured in serum from 24 patients with TK2 deficiency treated 1-49 months with oral deoxynucleosides. Patients were grouped according to age at treatment and biomarkers were analyzed at baseline and various time points after treatment initiation. GDF-15 was elevated on average 30-fold in children and 6-fold in adults before the start of treatment. There was a significant correlation between basal GDF-15 and severity based on pretreatment distance walked (6MWT) and weight (BMI). During treatment, GDF-15 significantly declined, and the decrease was accompanied by relevant clinical improvements. The decline was greater in the paediatric group, which included the most severe patients and showed the greatest clinical benefit, than in the adult patients. The decline of FGF-21 was less prominent and consistent. GDF-15 is a potential biomarker of severity and of therapeutic response for patients with TK2 deficiency. In addition, we show evidence of clinical benefit of deoxynucleoside treatment, especially when treatment is initiated at an early age.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Altered GDF15 and FGF21 Levels in Response to Strenuous Exercise, A Study in Marathon Runners

  • Campderrós, Laura
  • Sánchez-Infantes, David|||0000-0001-6086-7501
  • Villarroya, Joan
  • Nescolarde, Lexa|||0000-0001-6861-5106
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Cereijo, Rubén|||0000-0002-1108-230X
  • Roca, Emma|||0000-0002-2338-5877
  • Villarroya, Francesc|||0000-0003-1266-9142
Recreational marathon runners face strong physiological challenges. Assessment of potential biomarkers for the biological responses of runners will help to discriminate individual race responsiveness and their physiological consequences. This study sought to analyze the changes in the plasma levels of GDF15 and FGF21, novel endocrine factors related to metabolic stress, in runners following the strenuous exercise of a marathon race. Blood samples were obtained from eighteen male runners (mean ±SD, age: 41.7 ±5.0 years, BMI: 23.6 ± 1.8) 48 h before, immediately after, and 48 h after a marathon race, and from age-matched sedentary individuals. The level of GDF15, FGF21, and 38 additional biochemical and hematological parameters were determined. The basal levels of GDF15 and FGF21 did not differ between runners before the race and sedentary individuals. Significant increases in the mean levels of GDF15 (4.2-fold) and FGF21 (20-fold) were found in runners immediately after the race. The magnitudes of these increases differed markedly among individuals and did not correlate with each other. The GDF15 and FGF21 levels had returned to the basal level 48 h post-race. The post-race value of GDF15 (but not FGF21) correlated positively with increased total white cell count (r = 0.50, P = 0.01) and neutrophilia (r = 0.10, P = 0.01). GDF15 and FGF21 are transiently increased in runners following a marathon race. The induction of GDF15 levels is associated with alterations in circulating immune cells levels.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

ARMCX3 Mediates Susceptibility to Hepatic Tumorigenesis Promoted by Dietary Lipotoxicity

  • Mirra, Serena
  • Gavaldà i Navarro, Aleix|||0000-0001-8421-3174
  • Manso Sanz, Yasmina|||0000-0002-5788-4180
  • Higuera, Mónica|||0000-0002-3999-9603
  • Serrat, Román|||0000-0001-5530-2135
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Burgaya, Ferran|||0000-0002-6060-1081
  • Balibrea Del Castillo, José María|||0000-0002-0764-7179
  • Santamaría Monasterio, Eva|||0000-0003-0629-6175
  • Uriarte, Iker|||0000-0001-5237-7799
  • Berasain, Carmen|||0000-0001-7075-2476
  • Avila, Matias A.|||0000-0001-6570-3557
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Soriano García, Eduardo
  • Villarroya, Francesc|||0000-0003-1266-9142
An excess fat in the liver enhances the susceptibility to hepatic cancer. We found that Armcx3, a protein only known to date to play a role in neural development, is strongly increased in mouse liver in response to lipid availability and proliferation-inducing insults. In patients, the levels of hepatic Armcx3 are also increased in conditions of high exposure of the liver to fat. We wanted to determine the role of Armcx3 in the hepatocarcinogenesis favored by a high-fat diet. We generated mice with genetically driven suppression of Armcx3, and we found that they were protected against experimentally induced hepatic cancer, especially in conditions of a high-fat diet. Armcx3 was also found to promote hepatic cell proliferation through the interaction with Sox9, a known proliferation factor in hepatocellular carcinoma. Armcx3 is identified as a novel factor in meditating propensity to liver cancer in conditions of high hepatic lipid insults. ARMCX3 is encoded by a member of the Armcx gene family and is known to be involved in nervous system development and function. We found that ARMCX3 is markedly upregulated in mouse liver in response to high lipid availability, and that hepatic ARMCX3 is upregulated in patients with NAFLD and hepatocellular carcinoma (HCC). Mice were subjected to ARMCX3 invalidation (inducible ARMCX3 knockout) and then exposed to a high-fat diet and diethylnitrosamine-induced hepatocarcinogenesis. The effects of experimental ARMCX3 knockdown or overexpression in HCC cell lines were also analyzed. ARMCX3 invalidation protected mice against high-fat-diet-induced NAFLD and chemically induced hepatocarcinogenesis. ARMCX3 invalidation promoted apoptotic cell death and macrophage infiltration in livers of diethylnitrosamine-treated mice maintained on a high-fat diet. ARMCX3 downregulation reduced the viability, clonality and migration of HCC cell lines, whereas ARMCX3 overexpression caused the reciprocal effects. SOX9 was found to mediate the effects of ARMCX3 in hepatic cells, with the SOX9 interaction required for the effects of ARMCX3 on hepatic cell proliferation. In conclusion, ARMCX3 is identified as a novel molecular actor in liver physiopathology and carcinogenesis. ARMCX3 downregulation appears to protect against hepatocarcinogenesis, especially under conditions of high dietary lipid-mediated hepatic insult.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Secretory proteome of brown adipocytes in response to cAMP-mediated thermogenic activation

  • Villarroya, Joan
  • Cereijo, Rubén|||0000-0002-1108-230X
  • Girlat, Marta|||0000-0001-7968-4190
  • Villarroya, Francesc|||0000-0003-1266-9142
The secretory properties of brown adipose tissue are thought to contribute to the association between active brown fat and a healthy metabolic status. Although a few brown adipokines have been identified, a comprehensive knowledge of the brown adipose tissue secretome is lacking. Here, to examine the effects of thermogenic activation of brown adipocytes on protein secretion, we used isobaric tags for relative and absolute quantification (iTRAQ) analysis to determine how the secreted proteome of brown adipocytes (that detected in cell culture medium) differed in response to cAMP. Our results indicated that 56 secreted proteins were up-regulated in response to cAMP. Of them, nearly half (29) corresponded to extracellular matrix components and regulators. Several previously known adipokines, were also detected. Unexpectedly, we also found five components of the complement system. Only 15 secreted proteins were down-regulated by cAMP; of them three were ECM-related and none was related to the complement system. We observed a partial concordance between the cAMP-regulated release of proteins (both from proteomics and from antibody-based quantification of specific proteins) and the cAMP-mediated regulation of their encoding transcript for the up-regulated secreted proteins. However, a stronger concordance was seen for the down-regulated secreted proteins. The present results highlight the need to investigate previously unrecognized processes such as the role of extracellular matrix in thermogenic activation-triggered brown fat remodeling, as well as the intriguing question of how brown adipocyte-secreted complement factors contribute to the signaling properties of active brown adipose tissue.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue

  • Villarroya, Joan
  • Gallego-Escuredo, José Miguel
  • Delgado-Anglés, Alejandro|||0000-0002-6996-6327
  • Cairó, Montserrat
  • Moure, Ricardo
  • Mateo, María Gracia|||0000-0003-1389-9310
  • Domingo, Joan Carles|||0000-0002-6356-0836
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Girlat, Marta|||0000-0001-7968-4190
  • Villarroya, Francesc|||0000-0003-1266-9142
Fibroblast growth factor 21 (FGF21) has been proposed to be an antiaging hormone on the basis of experimental studies in rodent models. However, circulating FGF21 levels are increased with aging in rodents and humans. Moreover, despite the metabolic health-promoting effects of FGF21, the levels of this hormone are increased under conditions such as obesity and diabetes, an apparent incongruity that has been attributed to altered tissue responsiveness to FGF21. Here, we investigated serum FGF21 levels and expression of genes encoding components of the FGF21-response molecular machinery in adipose tissue from healthy elderly individuals (≥70 years old) and young controls. Serum FGF21 levels were increased in elderly individuals and were positively correlated with insulinemia and HOMA-IR, indices of mildly deteriorated glucose homeostasis. Levels of β-Klotho, the coreceptor required for cellular responsiveness to FGF21, were increased in subcutaneous adipose tissue from elderly individuals relative to those from young controls, whereas FGF receptor-1 levels were unaltered. Moreover, total ERK1/2 protein levels were decreased in elderly individuals in association with an increase in the ERK1/2 phosphorylation ratio relative to young controls. Adipose explants from aged and young mice respond similarly to FGF21 "ex vivo". Thus, in contrast to what is observed in obesity and diabetes, high levels of FGF21 in healthy aging are not associated with repressed FGF21-responsiveness machinery in adipose tissue. The lack of evidence for impaired FGF21 responsiveness in adipose tissue establishes a distinction between alterations in the FGF21 endocrine system in aging and chronic metabolic pathologies.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

ARMCX3 Mediates Susceptibility to Hepatic Tumorigenesis Promoted by Dietary Lipotoxicity

  • Mirra, Serena
  • Gavaldà-Navarro, Aleix
  • Manso, Yasmina
  • Serrat, Román
  • Salcedo Allende, Maria Teresa
  • Minguez Rosique, Beatriz
  • Higuera Urbano, Monica
  • Balibrea, José M.
Lipotoxicitat; Obesitat, Lipotoxicity; Obesity, Lipotoxicidad; Obesidad, ARMCX3 is encoded by a member of the Armcx gene family and is known to be involved in nervous system development and function. We found that ARMCX3 is markedly upregulated in mouse liver in response to high lipid availability, and that hepatic ARMCX3 is upregulated in patients with NAFLD and hepatocellular carcinoma (HCC). Mice were subjected to ARMCX3 invalidation (inducible ARMCX3 knockout) and then exposed to a high-fat diet and diethylnitrosamine-induced hepatocarcinogenesis. The effects of experimental ARMCX3 knockdown or overexpression in HCC cell lines were also analyzed. ARMCX3 invalidation protected mice against high-fat-diet-induced NAFLD and chemically induced hepatocarcinogenesis. ARMCX3 invalidation promoted apoptotic cell death and macrophage infiltration in livers of diethylnitrosamine-treated mice maintained on a high-fat diet. ARMCX3 downregulation reduced the viability, clonality and migration of HCC cell lines, whereas ARMCX3 overexpression caused the reciprocal effects. SOX9 was found to mediate the effects of ARMCX3 in hepatic cells, with the SOX9 interaction required for the effects of ARMCX3 on hepatic cell proliferation. In conclusion, ARMCX3 is identified as a novel molecular actor in liver physiopathology and carcinogenesis. ARMCX3 downregulation appears to protect against hepatocarcinogenesis, especially under conditions of high dietary lipid-mediated hepatic insult., The study was supported by grant 201337-30-31-32 Fundació la Marató de TV3, grant SAF2017-85722R (Ministerio de Economia y Competitividad) to F.V., grant PID2019-106764RB-C21/ AEI/ 10.13039/501100011033 from the Spanish Ministry of Science and a collaborative grant from CIBERNED to E.S, grant PI18/00961 (Instituto de Salud Carlos III) to B.M, and the Hepacare Project grant from Fundación La Caixa to M.A.A. and C.B. F.V. and E.S. are ICREA researchers.